trending Market Intelligence /marketintelligence/en/news-insights/trending/1TeuG-GgDmk2iulB0lZlnw2 content esgSubNav
In This List

Akorn names CEO

Blog

Insight Weekly: US stock market downturn; Chinese bank earnings; Europe's big tech bills

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022


Akorn names CEO

Akorn Inc. appointed Douglas Boothe as the company's president and CEO, effective Jan. 1, 2019.

Boothe most recently served as president of Impax Laboratories Inc.'s generics division, since Aug. 1, 2016. In addition, he acted as executive vice president and general manager of prescription pharmaceuticals at Perrigo Co. PLC. He was also CEO, COO and executive vice president of Actavis LLC.

Lake Forest, Ill.-based Akorn is a specialty generic pharmaceutical company that develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter consumer health products, and animal health pharmaceuticals.